Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src

Yan Zhao1, Maricarmen D Planas-Silva

  • 1Department of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA.

Cancer Letters
|November 26, 2008
PubMed

Insights

Tamoxifen-resistant breast cancer metastasis involves c-Src activation. Inhibiting c-Src signaling restores cell adhesion proteins, potentially preventing cancer spread.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • c-Src activation is linked to metastasis in tamoxifen-resistant breast cancer.
  • Understanding c-Src's role in cell adhesion is crucial for targeting metastasis.

Purpose of the Study:

  • To investigate the effect of c-Src activity on cell adhesion in tamoxifen-resistant breast cancer cells.
  • To determine if blocking c-Src can restore normal cell-cell adhesion.

Main Methods:

  • Utilized a tamoxifen-resistant MCF-7 cell variant (MTR-3) with elevated c-Src activity.
  • Analyzed the localization of adhesion proteins beta-catenin and E-cadherin.
  • Assessed the association between c-Src, beta-catenin, and E-cadherin.
  • Investigated the impact of blocking c-Src tyrosine kinase activity.

Main Results:

  • MTR-3 cells showed mislocalization of beta-catenin and E-cadherin into novel structures.
  • c-Src was found to be associated with beta-catenin/E-cadherin complexes.
  • Beta-catenin tyrosine phosphorylation was enhanced in MTR-3 cells.
  • Blocking c-Src activity reduced beta-catenin phosphorylation and restored protein localization at cell junctions.

Conclusions:

  • c-Src activation disrupts cell-cell adhesion by altering beta-catenin and E-cadherin localization.
  • Enhanced beta-catenin tyrosine phosphorylation by c-Src is a key mechanism in this disruption.
  • Inhibition of c-Src signaling may represent a therapeutic strategy to prevent metastasis in tamoxifen-resistant breast cancer.

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...